Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 24 of 88 · 4203 articles
This study describes a new nanoparticle (Ce‑TA) that reduced inflammation and tissue injury in a common mouse model of colitis, suggesting a possible future therapeutic avenue for IBD driven by antioxidant and...
Strictures cause obstructive symptoms and repeat surgery in Crohn’s disease; endoscopic options can relieve obstruction and potentially avoid or postpone surgery for some patients.
If disease activity hurts quality of life partly through low self-efficacy and (for UC) psychological distress, then boosting self-management confidence and identifying anxiety/depression could help improve...
A blood biomarker that flags higher risk for complicated Crohn's could help identify people who may need closer monitoring or earlier treatment escalation before clear symptoms or endoscopic inflammation appear.
Biologics can be critical for treating moderate-to-severe IBD, but cost and treatment failure limit access and long‑term use in this Indian cohort. Understanding uptake and reasons for stopping helps target interventions...
Patient engagement in treatment decisions can affect satisfaction, adherence, and care planning. This study identifies practical factors (treatment options, trusted providers, community support) associated with higher...
The study suggests quercetin can reduce inflammation and tissue damage markers in lab models of ulcerative colitis, pointing to ERK–MMP signaling as a possible mechanism. That could inform future preclinical research...
VEO-IBD often presents with severe, extensive disease and can include monogenic causes and early hepatobiliary complications; knowing common presentations and early management patterns helps families and clinicians plan...
People diagnosed as IBDU want to know whether their disease course, treatment needs, and chance of later being reclassified differ from typical UC or Crohn's disease.
The study targets TLR2 activation by bacterial curli, a mechanism linked to inflammation in IBD and other immune conditions. Engineering curli to inhibit TLR2 could become a strategy to create probiotics that reduce...
Disability and functional limitations (school, sports, travel, diet) are common early after pediatric IBD diagnosis and can persist for some children even after clinical remission. Recognizing and measuring disability...
A formulation that increases oral absorption of quercetin and reduces inflammation in animal models could point toward new flavonoid-based therapies for ulcerative colitis, but findings are preclinical.
Identifies IL-1RN and SERPINA1 as biomarkers linked to macrophage-driven inflammation in ulcerative colitis and shows TolDCs can reduce macrophage pro-inflammatory cytokine expression in lab experiments — findings that...
The study suggests that higher levels of objectively measured moderate-to-vigorous physical activity are associated with lower risk of developing ulcerative colitis, and that people may gain similar associations whether...
The study compares ustekinumab effectiveness between biologic‑naïve and biologic‑experienced Crohn’s patients and links clinical response to better quality of life and reduced anxiety — information relevant when...
The study reports that kaempferol reduced inflammation, fibrosis, and barrier damage in mouse and cell models of colitis — mechanisms directly relevant to IBD progression and symptoms.
Predicting which children with Crohn disease will need surgery — and roughly when — could help families and clinicians plan treatments, monitoring, and discussions about elective bowel resection earlier in the disease...
A non-invasive MRI method that correlates with histology and endoscopic scores could reduce the need for frequent colonoscopy for assessing IBD activity and help monitor treatment response, especially when endoscopy is...
People with IBD may be concerned about environmental exposures that could influence inflammation or worsen disease. This review explains why micro- and nanoplastics are biologically plausible contributors but also why...
The study proposes a new immunomodulatory approach—phosphatidylserine liposomes—that reduced inflammation in mouse colitis models and altered monocyte and T-cell responses, which could point toward future therapies for...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Capsule Endoscopy. The original article is from BMC Gastroenterology.
If MSCs can limit ferroptosis via CBS, that points to a new biological pathway that might be targeted to reduce intestinal inflammation in Crohn's disease. This could guide future lab research and eventually early-phase...
The study evaluates whether microbial networks differ between groups (including sexes) in IBD and other diseases using a rigorously tested method; that matters because robust methods are needed before microbiome patterns...
Based on the title and source metadata, this appears to be a case report related to Inflammatory bowel disease and Tests and monitoring. The original article is from The Turkish journal of gastroenterology : the official...
The paper reframes Crohn’s disease and ulcerative colitis in terms of dominant T-helper immune pathways (TH1 vs TH22), which could steer research on targeted immunologic treatments and biomarkers.
Crohn’s disease prevalence and new diagnoses are rising rapidly in Korea, especially among people in their 20s and 30s; that affects demand for diagnosis, long-term care, and affordable treatment.
This meta-analysis pulls together early trial evidence that TL1A antagonists may improve clinical, endoscopic, and histologic outcomes in both UC and CD and reports an overall acceptable short-term safety...
Delays and incomplete pre-referral screening are common in pediatric IBD and can affect how sick children are when they first see specialists. Better, standardized use of fecal calprotectin and abdominal ultrasound...
The study suggests a mechanism (reduced intestinal oxalate transport) that could make common “healthy” plant foods aggravate intestinal inflammation in some people with Crohn’s or ulcerative colitis, which could affect...
This work looks for molecular signals that might help explain how long-term ulcerative colitis can be connected to higher colorectal cancer risk. Identifying shared genes and spatial patterns could eventually guide...
New oral micro- and nanomedicine strategies aim to deliver drugs more selectively to diseased areas in the gut, which could eventually improve treatments for IBD and colorectal cancer by increasing local effects and...
Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Inflammatory bowel disease and Diet and lifestyle. The original article is from http://isrctn.com/.
Researchers planned to study whether patterns in the gut microbiome correlate with clinical diagnoses (including Crohn’s and UC), which could inform future biomarker work. The study is suspended, so no results are...
Understanding how patient-derived epithelial cells respond to inflammation could reveal mechanisms of poor mucosal healing in IBD and identify targets or biomarkers to improve repair. Organoid models from patient tissue...
A randomized trial tested whether adding dapagliflozin (an SGLT2 inhibitor) to mesalamine changes disease activity in adults with mild–moderate ulcerative colitis over 6 months. If effective and safe, it could suggest a...
This Phase 2 trial is testing a new oral drug (ATH-063) for adults with moderately to severely active ulcerative colitis who have not responded to prior biologic or advanced therapies, a group that often needs additional...
A validated, disease-specific self-care scale could help measure and track self-management behaviors that affect daily life and clinical outcomes for people with IBD, and support research and clinical care focused on...
Cognitive symptoms like fluctuating attention can accompany Crohn’s disease and appear linked to clinical activity; recognizing these changes may help patients and clinicians monitor overall disease impact beyond gut...
Sarcopenia (loss of muscle mass) appears common in people with IBD and is linked to markers of active disease and anemia; identifying it could point to patients who need nutritional or rehabilitation support.
How patients think about their IBD affects coping, treatment adherence, and quality of life. If different generations perceive illness threat and control differently, clinicians and care teams may need to tailor...
Patients and clinicians using ustekinumab may be able to use an early (around 3 months) drug concentration to help predict short-term remission, while routine repeated monitoring later on may be less informative for...
This highlights a new, biologically distinct drug target (IL‑7Rα) in ulcerative colitis that may help patients who do not respond to existing biologics, and it summarizes early clinical evidence for lusvertikimab while...
The study uses a mouse model of ulcerative colitis to test hemp seed oil and reports molecular and metabolic changes alongside reduced disease in the model. Patients and researchers may be interested because it explores...
A colon-targeted form of febuxostat reduced inflammation in a rat colitis model while keeping blood levels low, suggesting a way to repurpose an existing drug for IBD with potentially fewer systemic effects.
A plant-derived polysaccharide improved inflammation, gut barrier markers, and metabolic measures in a mouse model of diabetes-linked ulcerative colitis — findings that could point to new research directions for...
Patient-informed refinements to ePRO design and study operations could reduce burden and missing data in high-frequency daily symptom reporting, which matters for study quality and for patients asked to report symptoms...
Perceived stress affects quality of life and may influence symptom burden, disease management, and mental health in people with IBD. Updated PSQ benchmarks from a contemporary cohort help researchers and clinicians...
The study suggests that a soluble fiber from foxtail millet can lessen colitis in a mouse model by changing gut fungal communities and improving barrier proteins — pointing to a possible food‑based approach worth further...
